Computer-aided retrometabolic drug design: Soft drugs

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Soft drug design approaches aim to design new therapeutic agents that undergo facile, preferentially hydrolytic metabolism to produce inactive metabolites. This approach is general and can be used in essentially any therapeutic area, especially where the desired activity is localized, relatively short-lived or susceptible to easy titration. In most cases, this approach aims to design close steric and electronic analogs of an existing drug, which serves as a lead for the design. Therefore, computer programs that can generate virtual libraries of possible analogs and can provide quantitative tools to rank them on the basis of the closeness of their properties to the original lead are of particular relevance. Related aspects, including quantitative structure-metabolism relationships tools to predict hydrolytic stability are reviewed together with illustrative examples.

Original languageEnglish
Pages (from-to)923-933
Number of pages11
JournalExpert Opinion on Drug Discovery
Volume2
Issue number7
DOIs
StatePublished - Jul 1 2007

Fingerprint

Drug Design
Digital Libraries
Pharmaceutical Preparations
Software
Therapeutics
Lead

Keywords

  • Antedrug
  • Carboxylesterase
  • Metabolism
  • Prodrug
  • QSAR

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Computer-aided retrometabolic drug design : Soft drugs. / Buchwald, Peter.

In: Expert Opinion on Drug Discovery, Vol. 2, No. 7, 01.07.2007, p. 923-933.

Research output: Contribution to journalArticle

@article{ba6ee0d04c1840e0bc006c873231d8c4,
title = "Computer-aided retrometabolic drug design: Soft drugs",
abstract = "Soft drug design approaches aim to design new therapeutic agents that undergo facile, preferentially hydrolytic metabolism to produce inactive metabolites. This approach is general and can be used in essentially any therapeutic area, especially where the desired activity is localized, relatively short-lived or susceptible to easy titration. In most cases, this approach aims to design close steric and electronic analogs of an existing drug, which serves as a lead for the design. Therefore, computer programs that can generate virtual libraries of possible analogs and can provide quantitative tools to rank them on the basis of the closeness of their properties to the original lead are of particular relevance. Related aspects, including quantitative structure-metabolism relationships tools to predict hydrolytic stability are reviewed together with illustrative examples.",
keywords = "Antedrug, Carboxylesterase, Metabolism, Prodrug, QSAR",
author = "Peter Buchwald",
year = "2007",
month = "7",
day = "1",
doi = "10.1517/17460441.2.7.923",
language = "English",
volume = "2",
pages = "923--933",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Computer-aided retrometabolic drug design

T2 - Soft drugs

AU - Buchwald, Peter

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Soft drug design approaches aim to design new therapeutic agents that undergo facile, preferentially hydrolytic metabolism to produce inactive metabolites. This approach is general and can be used in essentially any therapeutic area, especially where the desired activity is localized, relatively short-lived or susceptible to easy titration. In most cases, this approach aims to design close steric and electronic analogs of an existing drug, which serves as a lead for the design. Therefore, computer programs that can generate virtual libraries of possible analogs and can provide quantitative tools to rank them on the basis of the closeness of their properties to the original lead are of particular relevance. Related aspects, including quantitative structure-metabolism relationships tools to predict hydrolytic stability are reviewed together with illustrative examples.

AB - Soft drug design approaches aim to design new therapeutic agents that undergo facile, preferentially hydrolytic metabolism to produce inactive metabolites. This approach is general and can be used in essentially any therapeutic area, especially where the desired activity is localized, relatively short-lived or susceptible to easy titration. In most cases, this approach aims to design close steric and electronic analogs of an existing drug, which serves as a lead for the design. Therefore, computer programs that can generate virtual libraries of possible analogs and can provide quantitative tools to rank them on the basis of the closeness of their properties to the original lead are of particular relevance. Related aspects, including quantitative structure-metabolism relationships tools to predict hydrolytic stability are reviewed together with illustrative examples.

KW - Antedrug

KW - Carboxylesterase

KW - Metabolism

KW - Prodrug

KW - QSAR

UR - http://www.scopus.com/inward/record.url?scp=34547487835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547487835&partnerID=8YFLogxK

U2 - 10.1517/17460441.2.7.923

DO - 10.1517/17460441.2.7.923

M3 - Article

C2 - 23484813

AN - SCOPUS:34547487835

VL - 2

SP - 923

EP - 933

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 7

ER -